問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of General Internal Medicine

Division of General Internal Medicine

更新時間:2023-09-19

謝茂
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

2Cases

2018-12-25 - 2024-07-04

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-12-25 - 2024-06-30

Phase III

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Condition/Disease

    Patients with Claudin (CLDN) 18.2 positive, HER2 negative, locally advanced unresectable or metastatic gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma

  • Test Drug

    Zolbetuximab (IMAB362)

Participate Sites
5Sites

Recruiting4Sites